---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Clinical trials questions"
description: "Clinical trials questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Comparisons, and Long-term results. Questions: How effective is Skyrizi for plaque psoriasis at 16 weeks (UltIMMa-1 and UltIMMa-2)? How many people on Skyrizi get completely clear skin (PASI 100)? Does Skyrizi keep skin clear at one year (PASI 90 at Week 52)? How quickly does Skyrizi start working for plaque psoriasis? 14 further questions follow. 18 questions quoted from 9 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Clinical trials questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications](https://www.evicenter.com/medical-information/skyrizi).

## Study results

<a id="skyrizi-ultimma-week-16"></a>

### How effective is Skyrizi for plaque psoriasis at 16 weeks (UltIMMa-1 and UltIMMa-2)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “PASI 90 at Week 16
> UltIMMa-1:
> SKYRIZI 75% (229/304), placebo 5% (5/102)
> UltIMMa-2:
> SKYRIZI 75% (220/294), placebo 2% (2/98)
>
> p<0.0001.
>
> sPGA 0/1 at Week 16
> UltIMMa-1:
> SKYRIZI 88% (267/304), placebo 8% (8/102)
> UltIMMa-2:
> SKYRIZI 84% (246/294), placebo 5% (5/98)”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=PASI%2090%20at%20Week%2016,84%25%20%28246%2F294%29%2C%20placebo%205%25%20%285%2F98%29)

> “NRI=Non-responder imputation.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=NRI%3DNon%2Dresponder%20imputation.)

> “UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis. Patients received SKYRIZI 150 mg at Week 0, Week 4, and every 12 weeks thereafter.<sup>1,2</sup>”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=UltIMMa%2D1%20%28N%3D506%29%20and%20UltIMMa%2D2%20%28N%3D491%29,4%2C%20and%20every%2012%20weeks)

> “In trials PsO-1 and PsO-2, 997 subjects were enrolled (including 598 subjects randomized to the 
> SKYRIZI 150 mg group, 200 subjects randomized to the placebo group, and 199 to the biologic 
> active control group). Subjects received treatment at Weeks 0, 4, and every 12 weeks thereafter.”

Source: [SKYRIZI: Prescribing information, page 22, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=22)

> “Four multicenter, randomized, double-blind trials [PsO-1 (NCT02684370), PsO-2 
> (NCT02684357), PsO-3 (NCT02672852), and PsO-4 (NCT02694523)] enrolled 2,109 subjects 
> 18 years of age and older with moderate-to-severe plaque psoriasis who had a body surface area 
> (BSA) involvement of ≥10%, a static Physician’s Global Assessment (sPGA) score of ≥3 
> (“moderate”) in the overall assessment (plaque thickness/induration, erythema, and scaling) of 
> psoriasis on a severity scale of 0 to 4, and a Psoriasis Area and Severity Index (PASI) score ≥12.  
> Overall, subjects had a median baseline PASI score of 17.8 and a median BSA of 20%. Baseline 
> sPGA score was 4 (“severe”) in 19% of subjects. A total of 10% of trial subjects had a history of 
> diagnosed psoriatic arthritis.  
> Across all trials, 38% of subjects had received prior phototherapy, 48% had received prior non-
> biologic systemic therapy, and 42% had received prior biologic therapy for the treatment of 
> psoriasis.”

Source: [SKYRIZI: Prescribing information, page 22, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=22)

Note: Trials PsO-1 and PsO-2 of the Prescribing Information enrolled 997 subjects, the combined enrollment of UltIMMa-1 (506) and UltIMMa-2 (491) on the Skyrizi HCP site, and report the same Week 16 rates in Table 8.

<a id="skyrizi-pasi-100-clear-skin"></a>

### How many people on Skyrizi get completely clear skin (PASI 100)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “Table 8. Efficacy Results at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis in 
> PsO-1 and PsO-2 
>
> PsO-1 
> PsO-2 
>
> SKYRIZI 
> (N=304) 
> n (%) 
> Placebo 
> (N=102) 
> n (%) 
> SKYRIZI 
> (N=294) 
> n (%) 
> Placebo 
> (N=98) 
> n (%) 
> sPGA 0 or 1 (“clear or 
> almost clear”)<sup>a</sup> 
> 267 (88) 
> 8 (8) 
> 246 (84) 
> 5 (5) 
> PASI 90<sup>a</sup> 
> 229 (75) 
> 5 (5) 
> 220 (75) 
> 2 (2) 
> sPGA 0 (“clear”) 
> 112 (37) 
> 2 (2) 
> 150 (51) 
> 3 (3) 
> PASI 100 
> 109 (36) 
> 0 (0) 
> 149 (51) 
> 2 (2) 
> <sup>a</sup> Co-primary endpoints”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

> “In PsO-1 and PsO-2 at Week 52, subjects receiving SKYRIZI achieved sPGA 0 (58% and 60%, 
> respectively), PASI 90 (82% and 81%, respectively), and PASI 100 (56% and 60%, 
> respectively).”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

> “Trial PsO-3 enrolled 507 subjects (407 randomized to SKYRIZI 150 mg and 100 to placebo). 
> Subjects received treatment at Weeks 0, 4, and every 12 weeks thereafter.  
> At Week 16, SKYRIZI was superior to placebo on the co-primary endpoints of sPGA 0 or 1 
> (84% SKYRIZI and 7% placebo) and PASI 90 (73% SKYRIZI and 2% placebo). The respective 
> response rates for SKYRIZI and placebo at Week 16 were: sPGA 0 (46% SKYRIZI and 1% 
> placebo); PASI 100 (47% SKYRIZI and 1% placebo); and PASI 75 (89% SKYRIZI and 8% 
> placebo).”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

Note: Table 8 columns are PsO-1 SKYRIZI (N=304), PsO-1 placebo (N=102), PsO-2 SKYRIZI (N=294), and PsO-2 placebo (N=98), in that order, each as n (%). Placebo was given only through Week 16.

<a id="skyrizi-one-year-pasi-90"></a>

### Does Skyrizi keep skin clear at one year (PASI 90 at Week 52)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “In PsO-1 and PsO-2 at Week 52, subjects receiving SKYRIZI achieved sPGA 0 (58% and 60%, 
> respectively), PASI 90 (82% and 81%, respectively), and PASI 100 (56% and 60%, 
> respectively).”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

> “In PsO-1 and PsO-2, among the subjects who received SKYRIZI and had PASI 100 at Week 16, 
> 80% (206/258) of the subjects who continued on SKYRIZI had PASI 100 at Week 52. For PASI 
> 90 responders at Week 16, 88% (398/450) of the subjects had PASI 90 at Week 52.”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

> “UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.<sup>1,2</sup>”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=UltIMMa%2D1%20%28N%3D506%29%20and%20UltIMMa%2D2%20%28N%3D491%29,with%20moderate%20to%20severe%20plaque)

Note: Trials PsO-1 and PsO-2 of the Prescribing Information have the combined enrollment (997) of UltIMMa-1 and UltIMMa-2 on the Skyrizi HCP site. Placebo was given only through Week 16.

<a id="skyrizi-how-fast"></a>

### How quickly does Skyrizi start working for plaque psoriasis?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “INTEGRATED RESULTS FROM UltIMMa-1 AND UltIMMa-2 AT SPECIFIC TIMEPOINTS
>
> AFTER 1 DOSE
> WEEK 4
>
> 58
> <sup>%</sup>
>
> MEAN PASI IMPROVEMENT<sup>‖¶</sup>
>
> (n=598)
>
> VS 9% FOR PLACEBO
>
> (n=200)
>
> PASI 90 AT WEEK 4 WAS 6%
>
> AFTER 2 DOSES
> WEEK 16
>
> 91
> <sup>%</sup>
>
> MEAN PASI IMPROVEMENT<sup>‖¶</sup>
>
> (n=598)
>
> VS 10% FOR PLACEBO
>
> (n=200)
>
> PASI 90 AT WEEK 16 WAS 75%”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=INTEGRATED%20RESULTS%20FROM%20UltIMMa%2D1%20AND%20UltIMMa%2D2%20AT,AT%20WEEK%2016%20WAS%2075%25)

> “<sup>‖</sup>As measured by change in PASI score from baseline; analysis conducted using last observation carried forward (LOCF) method.”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=measured%20by%20change%20in%20PASI,observation%20carried%20forward%20%28LOCF%29%20method.)

> “LIMITATIONS: Mean change in PASI at all timepoints and PASI 90 response at Week 4 were prespecified, nonranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=LIMITATIONS%3A%20Mean%20change%20in%20PASI,be%20regarded%20as%20statistically%20significant.)

> “<sup>¶</sup>Mean PASI improvement is an assessment of the average improvement from baseline to a set point in time in psoriatic signs of redness, thickness, scale, and body surface area of involvement.<sup>12</sup>”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=PASI%20improvement%20is%20an%20assessment,and%20body%20surface%20area%20of)

<a id="skyrizi-itch"></a>

### Does Skyrizi relieve psoriasis itching, pain, and burning?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “Improvements in signs and symptoms related to pain, redness, itching and burning at Week 16 
> compared to placebo were observed in both trials as assessed by the PSS. In PsO-1 and PsO-2, 
> about 30% of the subjects who received SKYRIZI achieved PSS 0 (“none”) at Week 16 
> compared to 1% of the subjects who received placebo.”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

<a id="skyrizi-immhance"></a>

### How effective was Skyrizi compared with placebo in trial PsO-3 (IMMhance)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “Trial PsO-3 enrolled 507 subjects (407 randomized to SKYRIZI 150 mg and 100 to placebo). 
> Subjects received treatment at Weeks 0, 4, and every 12 weeks thereafter.  
> At Week 16, SKYRIZI was superior to placebo on the co-primary endpoints of sPGA 0 or 1 
> (84% SKYRIZI and 7% placebo) and PASI 90 (73% SKYRIZI and 2% placebo). The respective 
> response rates for SKYRIZI and placebo at Week 16 were: sPGA 0 (46% SKYRIZI and 1% 
> placebo); PASI 100 (47% SKYRIZI and 1% placebo); and PASI 75 (89% SKYRIZI and 8% 
> placebo).”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

> “IMMhance was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the impact of treatment withdrawal and re-treatment of SKYRIZI compared to placebo in adult patients with moderate to severe plaque psoriasis.<sup>1,5</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=IMMhance%20was%20a%20Phase%203%2C,with%20moderate%20to%20severe%20plaque)

Note: The Prescribing Information reports a 507-subject placebo-controlled trial with withdrawal and re-treatment as PsO-3 (NCT02672852); the Skyrizi HCP safety page describes IMMhance as its Phase 3 placebo-controlled withdrawal and re-treatment study. Neither document names the trial both ways.

<a id="skyrizi-stopping-treatment"></a>

### Does psoriasis come back if Skyrizi is stopped?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “In PsO-3, subjects who were originally on SKYRIZI and had sPGA 0 or 1 at Week 28 were re-
> randomized to continue SKYRIZI every 12 weeks or withdrawal of therapy. At Week 52, 87% 
> (97/111) of the subjects re-randomized to continue treatment with SKYRIZI had sPGA 0 or 1 
> compared to 61% (138/225) who were re-randomized to withdrawal of SKYRIZI.”

Source: [SKYRIZI: Prescribing information, page 23, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=23)

> “IMMhance was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the impact of treatment withdrawal and re-treatment of SKYRIZI compared to placebo in adult patients with moderate to severe plaque psoriasis.<sup>1,5</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=IMMhance%20was%20a%20Phase%203%2C,with%20moderate%20to%20severe%20plaque)

Note: Only subjects originally on Skyrizi with sPGA 0 or 1 at Week 28 were re-randomized. The Prescribing Information reports a 507-subject placebo-controlled trial with withdrawal and re-treatment as PsO-3 (NCT02672852); the Skyrizi HCP safety page describes IMMhance as its Phase 3 placebo-controlled withdrawal and re-treatment study. Neither document names the trial both ways.

<a id="skyrizi-scalp"></a>

### Does Skyrizi work for scalp psoriasis?

Applies to: Adults with moderate-to-severe plaque psoriasis of the scalp

> “The efficacy of SKYRIZI was assessed in a multicenter, randomized, double-blind, placebo-
> controlled trial [PsO-5 (NCT05969223)] that enrolled subjects 18 years of age and older with 
> moderate-to-severe plaque psoriasis of the scalp (Trial S), defined as Psoriasis Scalp Severity 
> Index (PSSI) ≥12, scalp Investigator Global Assessment (scalp IGA) ≥3 (“moderate”), and ≥30% 
> of the scalp affected, or moderate-to-severe plaque psoriasis of the genital area (Trial G), defined 
> as static Physician’s Global Assessment of Genitalia (sPGA-G) ≥3 (“moderate”) at baseline. All 
> subjects had BSA ≥1% and sPGA ≥3 (“moderate”) at baseline. 
> In trial PsO-5, subjects were randomized to receive either SKYRIZI 150 mg or placebo 
> subcutaneously at Weeks 0 and 4. Starting at Week 16, all subjects received SKYRIZI 150 mg 
> every 12 weeks until the last dose at Week 40.”

Source: [SKYRIZI: Prescribing information, page 24, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=24)

> “PsO-5 Trial S enrolled 105 subjects with moderate-to-severe plaque psoriasis of the scalp.”

Source: [SKYRIZI: Prescribing information, page 24, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=24)

> “Table 9. Efficacy Results at Week 16 in Adults with Moderate-to-Severe Psoriasis of the 
> Scalp in PsO-5 Trial S 
> Endpoint 
> SKYRIZI 
> (N=51) 
> n (%) 
> Placebo 
> (N=54) 
> n (%) 
> Treatment 
> Difference  
> (95% CI) 
> scalp IGA of 0 or 1 (“clear or almost 
> clear”)<sup>a</sup> 
> 31 (61) 
> 7 (13) 
> 47 
> (31, 63) 
> PSSI 90<sup>b</sup> 
> 27 (53) 
> 7 (13) 
> 40 
> (24, 55) 
> PSSI 100<sup>c</sup> 
> 23 (45) 
> 7 (13) 
> 31 
> (15, 47) 
> <sup>a</sup> Primary endpoint 
> <sup>b</sup> Achievement of ≥90% improvement from baseline in PSSI 
> <sup>c</sup> Achievement of 100% improvement from baseline in PSSI”

Source: [SKYRIZI: Prescribing information, page 24, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=24)

> “73% OF PATIENTS ACHIEVED CLEAR OR ALMOST CLEAR SCALP (NRI) AT 1 YEAR (OL)<sup>3,4</sup>”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=73%25%20OF%20PATIENTS%20ACHIEVED%20CLEAR,SCALP%20%28NRI%29%20AT%201%20YEAR)

> “Achievement of scalp IGA 0 or 1 at Week 52 was a prespecified, nonranked endpoint and not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=Achievement%20of%20scalp%20IGA%200,be%20regarded%20as%20statistically%20significant.)

> “In an open-label study or period, there is potential for enrichment; awareness of active treatment may cause bias to overall treatment effect.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=In%20an%20open%2Dlabel%20study%20or,bias%20to%20overall%20treatment%20effect.)

Note: Table 9 columns are SKYRIZI (N=51), placebo (N=54), and the treatment difference (95% CI), in that order. The Week 52 result is from the UnlIMMited Study-S section of the scalp and genital page of the Skyrizi HCP site; all subjects received open-label Skyrizi from Week 16.

<a id="skyrizi-genital"></a>

### Does Skyrizi work for genital psoriasis?

Applies to: Adults with moderate-to-severe plaque psoriasis of the genital area

> “The efficacy of SKYRIZI was assessed in a multicenter, randomized, double-blind, placebo-
> controlled trial [PsO-5 (NCT05969223)] that enrolled subjects 18 years of age and older with 
> moderate-to-severe plaque psoriasis of the scalp (Trial S), defined as Psoriasis Scalp Severity 
> Index (PSSI) ≥12, scalp Investigator Global Assessment (scalp IGA) ≥3 (“moderate”), and ≥30% 
> of the scalp affected, or moderate-to-severe plaque psoriasis of the genital area (Trial G), defined 
> as static Physician’s Global Assessment of Genitalia (sPGA-G) ≥3 (“moderate”) at baseline. All 
> subjects had BSA ≥1% and sPGA ≥3 (“moderate”) at baseline. 
> In trial PsO-5, subjects were randomized to receive either SKYRIZI 150 mg or placebo 
> subcutaneously at Weeks 0 and 4. Starting at Week 16, all subjects received SKYRIZI 150 mg 
> every 12 weeks until the last dose at Week 40.”

Source: [SKYRIZI: Prescribing information, page 24, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=24)

> “PsO-5 Trial G enrolled 109 subjects with moderate-to-severe plaque psoriasis of the genital area.”

Source: [SKYRIZI: Prescribing information, page 25, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=25)

> “Table 10. Efficacy Results at Week 16 in Adults with Moderate-to-Severe Psoriasis of the 
> Genital Area in PsO-5 Trial G 
> Endpoint 
> SKYRIZI 
> (N=55) 
> n (%) 
> Placebo 
> (N=54) 
> n (%) 
> Treatment 
> Difference  
> (95% CI) 
> sPGA-G of 0 or 1 (“clear or 
> minimal”)<sup>a</sup> 
> 38 (69) 
> 7 (13) 
> 57 
> (42, 72) 
> sPGA-G of 0 (“clear”) 
> 28 (51) 
> 3 (6) 
> 47 
> (33, 61) 
> GPI-NRS reduction of ≥4-point from 
> baseline<sup>b</sup> 
> N=41 
> 20 (49) 
> N=45 
> 3 (7) 
> 43 
> (27, 59) 
> GenPs-SFQ item 2 score of 0 (never) 
> or 1 (rarely)<sup>c,d</sup> 
> N=31 
> 22 (71) 
> N=32 
> 7 (22) 
> 46 
> (27, 66) 
> <sup>a</sup> Primary endpoint 
> <sup>b</sup> Improvement of genital itch severity as measured by a reduction of at least 4 points in the 11-
> point Genital Psoriasis Itch (GPI) Numeric Rating Scale (NRS) from the Genital Psoriasis 
> Symptom Scale (GPSS) among subjects with baseline score ≥4  
> <sup>c</sup> Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 (In the past week, how 
> often did your genital psoriasis limit the frequency of your sexual activity?) score ranges from 
> 0 to 4 (0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = always); where higher scores 
> indicate greater limitations on the frequency of sexual activity in the past week  
> <sup>d</sup> Among subjects with baseline score ≥2”

Source: [SKYRIZI: Prescribing information, page 25, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=25)

> “82% OF PATIENTS ACHIEVED COMPLETELY CLEAR OR ALMOST CLEAR SKIN
> IN GENITAL AREA (NRI) AT 1 YEAR (OL)<sup>3,4</sup>”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=82%25%20OF%20PATIENTS%20ACHIEVED%20COMPLETELY,AREA%20%28NRI%29%20AT%201%20YEAR)

> “Achievement of sPGA-G of O or 1 at Week 4 and Week 52 were prespecified, nonranked endpoints and not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=Achievement%20of%20sPGA%2DG%20of%20O,be%20regarded%20as%20statistically%20significant.)

> “In an open-label study or period, there is potential for enrichment; awareness of active treatment may cause bias to overall treatment effect.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=In%20an%20open%2Dlabel%20study%20or%20period%2C%20there%20is%20potential%20for%20enrichment%3B%20awareness%20of%20active%20treatment%20may%20cause%20bias%20to%20overall%20treatment%20effect.,-The%20sPGA%2DG%20is)

Note: Table 10 columns are SKYRIZI (N=55), placebo (N=54), and the treatment difference (95% CI), in that order. The Week 52 result is from the UnlIMMited Study-G section of the scalp and genital page of the Skyrizi HCP site; all subjects received open-label Skyrizi from Week 16.

<a id="skyrizi-nail-palmoplantar"></a>

### Does Skyrizi work for palmoplantar (hand and foot) psoriasis?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “IMMprint was a Phase 3b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, 52-week study that assessed the safety and efficacy of SKYRIZI (150 mg) vs placebo for the treatment of moderate to severe plaque psoriasis in adult patients with palmoplantar (non-pustular) involvement. The primary endpoint evaluated the proportion achieving pplGA of O or 1 with ≥2-point reduction from baseline at Week 16. Additional ranked secondary endpoints included PPASI 75, PPASI 90, sPGA 0/1, and PPASI 100 at Week 16.<sup>5</sup>”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=IMMprint%20was%20a%20Phase%203b%2C,and%20PPASI%20100%20at%20Week)

> “SKYRIZI MET THE PRIMARY ENDPOINT OF ppIGA 0/1 AT WEEK 16
> WITH RESPONSE RATES OBSERVED AT WEEK 52<sup>5</sup>”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=SKYRIZI%20MET%20THE%20PRIMARY%20ENDPOINT,RESPONSE%20RATES%20OBSERVED%20AT%20WEEK)

> “All endpoints at Week 52 were prespecified, nonranked endpoints and were not controlled for multiple comparisons. Therefore, no statistical or clinical conclusions can be drawn.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=All%20endpoints%20at%20Week%2052,clinical%20conclusions%20can%20be%20drawn.)

> “IN AN INTEGRATED SUBANALYSIS OF UltlMMa-1 and UltlMMa-2 AT WEEK 52 (LOCF)”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=IN%20AN%20INTEGRATED%20SUBANALYSIS%20OF%20UltlMMa%2D1%20and%20UltlMMa%2D2%20AT%20WEEK%2052%20%28LOCF%29)

> “91% MEAN IMPROVEMENT IN PALMOPLANTAR PSORIASIS
>
> (MEAN CHANGE IN PPASI FROM BASELINE) n=184”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=91%25%20MEAN%20IMPROVEMENT%20IN%20PALMOPLANTAR,IN%20PPASI%20FROM%20BASELINE%29%20n%3D184)

> “MEAN PATIENT SCORES AT BASELINE (SD)
>
> PSSI
>
> 18.2 (14.7)
>
> PPASI
>
> 2.42 (6.0)
>
> NAPSI
>
> 13.6 (18.4)”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=MEAN%20PATIENT%20SCORES%20AT%20BASELINE,13.6%20%2818.4%29)

> “Mean change in PSSI, PPASI, and NAPSI were prespecified, nonranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=Mean%20change%20in%20PSSI%2C%20PPASI%2C,be%20regarded%20as%20statistically%20significant.)

> “Based on analysis of integrated data from UltIMMa-1 and UltIMMa-2 at Week 52 of patients receiving SKYRIZI who had a baseline score of >0 on NAPSI, PSSI, and PPASI, respectively. Missing NAPSI, PSSI, and PPASI data were imputed as last observation carried forward (LOCF).<sup>5</sup>”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=Based%20on%20analysis%20of%20integrated,as%20last%20observation%20carried%20forward)

Note: The page shows the IMMprint response rates only in a graphic. The integrated palmoplantar figure (PPASI) comes from a subanalysis of UltIMMa-1 and UltIMMa-2 that the page cites to a 2019 conference poster (Elewski et al.). The Prescribing Information does not report palmoplantar outcomes.

<a id="skyrizi-nail"></a>

### Does Skyrizi improve nail psoriasis?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “IN AN INTEGRATED SUBANALYSIS OF UltlMMa-1 and UltlMMa-2 AT WEEK 52 (LOCF)”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=IN%20AN%20INTEGRATED%20SUBANALYSIS%20OF%20UltlMMa%2D1%20and%20UltlMMa%2D2%20AT%20WEEK%2052%20%28LOCF%29)

> “66<sup>%</sup>
>
> MEAN IMPROVEMENT IN
> NAIL PSORIASIS
>
> (MEAN CHANGE IN NAPSI FROM BASELINE)
>
> n=361”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=MEAN%20IMPROVEMENT%20IN-,NAIL%20PSORIASIS,n%3D361)

> “MEAN PATIENT SCORES AT BASELINE (SD)
>
> PSSI
>
> 18.2 (14.7)
>
> PPASI
>
> 2.42 (6.0)
>
> NAPSI
>
> 13.6 (18.4)”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=MEAN%20PATIENT%20SCORES%20AT%20BASELINE,13.6%20%2818.4%29)

> “Mean change in PSSI, PPASI, and NAPSI were prespecified, nonranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=Mean%20change%20in%20PSSI%2C%20PPASI%2C,be%20regarded%20as%20statistically%20significant.)

> “Based on analysis of integrated data from UltIMMa-1 and UltIMMa-2 at Week 52 of patients receiving SKYRIZI who had a baseline score of >0 on NAPSI, PSSI, and PPASI, respectively. Missing NAPSI, PSSI, and PPASI data were imputed as last observation carried forward (LOCF).<sup>5</sup>”

Source: [SKYRIZI: SKYRIZI® - Scalp, Genital, Palmoplantar, & Nail Psoriasis Treatment, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar#:~:text=Based%20on%20analysis%20of%20integrated,as%20last%20observation%20carried%20forward)

Note: The integrated nail figure (NAPSI) comes from a subanalysis of UltIMMa-1 and UltIMMa-2 that the page cites to a 2019 conference poster (Elewski et al.). The Prescribing Information does not report nail outcomes.

## Comparisons

<a id="skyrizi-vs-stelara"></a>

### Skyrizi vs Stelara (ustekinumab): which was more effective in UltIMMa-1 and UltIMMa-2?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “sPGA 0/1 at Week 16<sup>1,2</sup>:
>
> UltIMMa-1:
> SKYRIZI 88%, ustekinumab 63%, placebo 8%
>
> UltIMMa-2:
> SKYRIZI 84%, ustekinumab 62%, placebo 5%”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=sPGA%200%2F1%20at%20Week,84%25%2C%20ustekinumab%2062%25%2C%20placebo%205%25)

> “Co-primary endpoints were PASI 90 and sPGA 0/1 response vs placebo at Week 16. Secondary endpoints included PASI 90 and sPGA 0/1 response vs STELARA* and PASI 100 response vs placebo and STELARA at Week 16.<sup>1,2</sup>”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=Co%2Dprimary%20endpoints%20were%20PASI%2090,placebo%20and%20STELARA%20at%20Week)

> “In trials PsO-1 and PsO-2, 997 subjects were enrolled (including 598 subjects randomized to the 
> SKYRIZI 150 mg group, 200 subjects randomized to the placebo group, and 199 to the biologic 
> active control group). Subjects received treatment at Weeks 0, 4, and every 12 weeks thereafter.”

Source: [SKYRIZI: Prescribing information, page 22, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=22)

> “NRI=Nonresponder imputation.”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=NRI%3DNonresponder%20imputation.)

> “UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.<sup>1,2</sup>”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=UltIMMa%2D1%20%28N%3D506%29%20and%20UltIMMa%2D2%20%28N%3D491%29,with%20moderate%20to%20severe%20plaque)

> “The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=The%20ustekinumab%20used%20as%20a,ustekinumab%20has%20not%20been%20established.)

Note: The comparison page shows the Week 16 PASI 90 and PASI 100 rates vs ustekinumab in a graphic whose values are not in the page text. The Prescribing Information does not report the ustekinumab results.

<a id="skyrizi-vs-humira"></a>

### Skyrizi vs Humira (adalimumab): which was more effective for plaque psoriasis (IMMvent)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “72% OF SKYRIZI PATIENTS ACHIEVED PASI 90 VS 47% OF HUMIRA PATIENTS (NRI)<sup>2</sup>
>
> WEEK 16 RESULTS (PART A)
>
> *p<0.0001”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=72%25%20OF%20SKYRIZI%20PATIENTS%20ACHIEVED,%2Ap%3C0.0001)

> “Part A Co-Primary Endpoints: PASI 90 and sPGA 0/1 at Week 16”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=Part%20A%20Co%2DPrimary%20Endpoints%3A%20PASI%2090%20and%20sPGA%200%2F1%20at%20Week%2016)

> “IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.<sup>3</sup>”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=IMMvent%20was%20a%20Phase%203%2C,severe%20plaque%20psoriasis%20over%2044)

> “In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.<sup>3</sup>”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=In%20Part%20A%20of%20the,Part%20B%20remained%20on%20every%2D12%2Dweek)

> “NRI=Nonresponder imputation.”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=AND%20BASELINE%20CHARACTERISTICS-,NRI%3DNonresponder%20imputation.)

Note: IMMvent is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Reich et al., Lancet 2019. The page text gives no denominators for these rates.

<a id="skyrizi-vs-cosentyx"></a>

### Skyrizi vs Cosentyx (secukinumab): which was more effective in IMMerge?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “87% OF SKYRIZI PATIENTS ACHIEVED PASI 90 AT WEEK 52 VS 57% OF COSENTYX® (secukinumab) PATIENTS (NRI)<sup>2</sup>”

Source: [SKYRIZI: SKYRIZI® vs COSENTYX® Efficacy Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-cosentyx#:~:text=87%25%20OF%20SKYRIZI%20PATIENTS%20ACHIEVED,57%25%20OF%20COSENTYX%C2%AE%20%28secukinumab%29%20PATIENTS)

> “The head-to-head study was an open-label, assessor-blinded, 52-week study where patients were randomized 1:1 to receive either SKYRIZI 150 mg (two 75 mg injections) at Weeks 0, 4, and every 12 weeks until the last dose at Week 40; or COSENTYX* 300 mg (two 150 mg injections) at Weeks 0, 1, 2, 3, 4, and every 4 weeks until the last dose at Week 48.<sup>2</sup>”

Source: [SKYRIZI: SKYRIZI® vs COSENTYX® Efficacy Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-cosentyx#:~:text=The%20head%2Dto%2Dhead%20study%20was%20an,4%20weeks%20until%20the%20last%20dose%20at%20Week)

> “NRI=Nonresponder imputation; ITT=Intent-to-treat.”

Source: [SKYRIZI: SKYRIZI® vs COSENTYX® Efficacy Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-cosentyx#:~:text=NRI%3DNonresponder%20imputation%3B%20ITT%3DIntent%2Dto%2Dtreat.)

> “In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab is not publicly available.<sup>3</sup>”

Source: [SKYRIZI: SKYRIZI® vs COSENTYX® Efficacy Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-cosentyx#:~:text=In%20this%20study%2C%2046%20patients,non%2DUS%20secukinumab%20is%20not%20publicly)

Note: IMMerge is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Warren et al., Br J Dermatol 2021. The page text gives no denominators for these rates.

<a id="skyrizi-vs-otezla"></a>

### Skyrizi vs Otezla (apremilast): which was more effective for moderate plaque psoriasis (IMMpulse)?

Applies to: Adults with moderate plaque psoriasis who are candidates for systemic therapy

> “IMMpulse: a Phase 4, 2-part, open-label, assessor-blinded study”

Source: [SKYRIZI: SKYRIZI® vs OTEZLA® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla#:~:text=IMMpulse%3A%20a%20Phase%204%2C%202%2Dpart%2C%20open%2Dlabel%2C%20assessor%2Dblinded%20study)

> “Co-Primary Endpoints: PASI 90 and sPGA 0/1 at Week 16”

Source: [SKYRIZI: SKYRIZI® vs OTEZLA® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla#:~:text=Co%2DPrimary%20Endpoints%3A%20PASI%2090%20and%20sPGA%200%2F1%20at%20Week%2016)

> “sPGA 0/1 at Week 16: SKYRIZI: 75% (n=89/118), OTEZLA: 18% (n=43/234)”

Source: [SKYRIZI: SKYRIZI® vs OTEZLA® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla#:~:text=sPGA%200%2F1%20at%20Week%2016%3A%20SKYRIZI%3A%2075%25%20%28n%3D89%2F118%29%2C%20OTEZLA%3A%2018%25%20%28n%3D43%2F234%29)

> “Ranked Secondary Endpoint: PASI 75 at Week 16”

Source: [SKYRIZI: SKYRIZI® vs OTEZLA® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla#:~:text=Ranked%20Secondary%20Endpoint%3A%20PASI%2075%20at%20Week%2016)

> “PASI 75 at Week 16: SKYRIZI: 85% (n=100/118), OTEZLA: 19% (n=44/234)”

Source: [SKYRIZI: SKYRIZI® vs OTEZLA® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla#:~:text=PASI%2075%20at%20Week%2016%3A%20SKYRIZI%3A%2085%25%20%28n%3D100%2F118%29%2C%20OTEZLA%3A%2019%25%20%28n%3D44%2F234%29)

> “IMMpulse was a 52-week, Phase 4, multicenter, randomized, open-label, efficacy assessor-blinded study of SKYRIZI compared to OTEZLA for the treatment of adults with moderate plaque psoriasis who are candidates for systemic therapy. Patients were randomly assigned (1:2) to either SKYRIZI 150 mg as a single subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter or OTEZLA 30 mg orally twice daily, post-titration per label. The co-primary endpoints of Period A were achievement of PASI 90 and sPGA 0/1 at Week 16. The primary endpoint of Period B was achievement of PASI 90 at Week 52 among patients who failed to achieve PASI 75 with OTEZLA at Week 16. Patients were eligible for inclusion in this study if they had baseline PASI ≥12, BSA 10%-15%, and sPGA=3.<sup>2</sup>”

Source: [SKYRIZI: SKYRIZI® vs OTEZLA® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla#:~:text=IMMpulse%20was%20a%2052%2Dweek%2C%20Phase,PASI%20%E2%89%A512%2C%20BSA%2010%25%2D15%25%2C%20and)

> “NRI-MI=nonresponder imputation incorporating multiple imputation for missing data due to COVID-19; PASI=Psoriasis Area and Severity Index; PASI 75=≥75% improvement in Psoriasis Area and Severity Index; PASI 90=≥90% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician’s Global Assessment rating of “clear or almost clear.””

Source: [SKYRIZI: SKYRIZI® vs OTEZLA® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla#:~:text=NRI%2DMI%3Dnonresponder%20imputation%20incorporating%20multiple%20imputation,of%20%E2%80%9Cclear%20or%20almost%20clear.%E2%80%9D)

Note: IMMpulse is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Stein Gold et al., Br J Dermatol 2023. The page shows the Week 16 PASI 90 rates in a graphic whose values are not in the page text.

<a id="skyrizi-vs-sotyktu"></a>

### Skyrizi vs Sotyktu (deucravacitinib): which was more effective for moderate plaque psoriasis (IMMpactful)?

Applies to: Adults with moderate plaque psoriasis who are candidates for systemic therapy

> “IMMpactful: a Phase 4, 2-part, open-label, assessor-blinded study”

Source: [SKYRIZI: SKYRIZI® vs SOTYKTU® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-sotyktu#:~:text=IMMpactful%3A%20a%20Phase%204%2C%202%2Dpart%2C%20open%2Dlabel%2C%20assessor%2Dblinded%20study)

> “Co-primary endpoints: PASI 90 and sPGA 0/1 at Week 16”

Source: [SKYRIZI: SKYRIZI® vs SOTYKTU® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-sotyktu#:~:text=Co%2Dprimary%20endpoints%3A%20PASI%2090%20and%20sPGA%200%2F1%20at%20Week%2016)

> “sPGA 0/1 at Week 16: SKYRIZI: 80% (n=105/131), SOTYKTU: 40% (n=104/262)”

Source: [SKYRIZI: SKYRIZI® vs SOTYKTU® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-sotyktu#:~:text=sPGA%200%2F1%20at%20Week%2016%3A%20SKYRIZI%3A%2080%25%20%28n%3D105%2F131%29%2C%20SOTYKTU%3A%2040%25%20%28n%3D104%2F262%29)

> “IMMpactful is a 52-week, Phase 4, randomized, open-label, efficacy assessor-blinded study of SKYRIZI compared to SOTYKTU for the treatment of bio-naive adults with moderate plaque psoriasis who are candidates for systemic therapy. Patients were randomly assigned (1:2) to either SKYRIZI 150 mg as a single subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter or SOTYKTU 6 mg daily per label.<sup>2</sup>”

Source: [SKYRIZI: SKYRIZI® vs SOTYKTU® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-sotyktu#:~:text=IMMpactful%20is%20a%2052%2Dweek%2C%20Phase,SOTYKTU%206%20mg%20daily%20per)

> “<sup>†</sup>IMMpactful NRI-MI=nonresponder imputations (NRI) incorporating multiple imputations (MI) for missing data that can be reasonably assumed to be missing at random. PASI 90=≥90% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician’s Global Assessment rating of “clear or almost clear."”

Source: [SKYRIZI: SKYRIZI® vs SOTYKTU® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-sotyktu#:~:text=NRI%2DMI%3Dnonresponder%20imputations%20%28NRI%29%20incorporating%20multiple,of%20%E2%80%9Cclear%20or%20almost%20clear.%22)

Note: IMMpactful is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Magnolo et al., Dermatol Ther (Heidelb) 2026. The page shows the Week 16 PASI 90 rates in a graphic whose values are not in the page text.

## Long-term results

<a id="skyrizi-long-term-pasi-90"></a>

### How many people on Skyrizi still have PASI 90 after 2.5 years?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “86% OF SKYRIZI PATIENTS ACHIEVED PASI 90 AT WEEK 52 AND 87% AT WEEK 136<sup>3,4</sup>
>
> INTEGRATED RESULTS FROM ULTIMMA-1 & -2 PATIENTS (LOCF)”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=86%25%20OF%20SKYRIZI%20PATIENTS%20ACHIEVED,ULTIMMA%2D1%20%26%20%2D2%20PATIENTS%20%28LOCF%29)

> “The randomized controlled trial data shown here are integrated results from UltIMMa-1 and -2. The open-label extension (OLE) data are a sub-analysis of LIMMitless and include only patients from UltIMMa-1 and -2 who completed the RCT and then enrolled in the OLE. LIMMitless is an OLE for which patients who completed either UltIMMa trial, IMMhance, or IMMvent were eligible to participate.<sup>4-7</sup>”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=The%20randomized%20controlled%20trial%20data%20shown%20here%20are%20integrated%20results,or%20IMMvent%20were%20eligible%20to)

> “In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=In%20an%20open%2Dlabel%20extension%2C%20there%20is%20potential%20for%20enrichment%20of,the%20drug%20often%20drop%20out.)

Note: These figures are in the section of the comparison page on patients who started and remained on Skyrizi; the page text gives no denominators. The open-label extension data are not in the Prescribing Information.

<a id="skyrizi-six-year-results"></a>

### What skin improvement does Skyrizi show after about 6 years (LIMMitless)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “OPEN-LABEL EXTENSION (OLE), AS OBSERVED<sup>7</sup>
>
> AFTER 26 DOSES
> WEEK 304
>
> 97
> <sup>%</sup>
>
> MEAN PASI IMPROVEMENT<sup>¶</sup>
>
> (n=374)”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=OPEN%2DLABEL%20EXTENSION%20%28OLE%29%2C%20AS,%28n%3D374%29)

> “<sup>¶</sup>Mean PASI improvement is an assessment of the average improvement from baseline to a set point in time in psoriatic signs of redness, thickness, scale, and body surface area of involvement.<sup>12</sup>”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=PASI%20improvement%20is%20an%20assessment,and%20body%20surface%20area%20of)

> “LIMMitless is an open-label extension for which patients who completed UltIMMa-1 or -2, IMMvent, or IMMhance were eligible to participate. The data presented here are a subanalysis of LIMMitless and include only patients from UltIMMa-1 and -2. 525 patients from UltIMMa-1 and -2 have enrolled in LIMMitless at this time.<sup>7-9</sup>”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=LIMMitless%20is%20an%20open%2Dlabel%20extension,enrolled%20in%20LIMMitless%20at%20this)

> “AO DISCLOSURE: In an as observed analysis (AO), missing visit data were excluded from calculations for that visit, which may increase the percent of responders. All observed data were used regardless of premature discontinuation of study drug, initiation of concomitant medication, or rescue medication. The same patient may not have a response at each timepoint.”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=AO%20DISCLOSURE%3A%20In%20an%20as,a%20response%20at%20each%20timepoint.)

> “OLE LIMITATIONS: In an open-label extension, there is a potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=as%20statistically%20significant.-,OLE%20LIMITATIONS%3A%20In%20an%20open%2Dlabel%20extension%2C%20there%20is%20a%20potential,the%20drug%20often%20drop%20out.)

Note: The efficacy page shows the Week 304 PASI 90 and PASI 100 rates in a graphic whose values are not in the page text; the open-label extension data are not in the Prescribing Information.

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage)
